Home › Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Pag-aaral pangklinika para sa Precursor T-Cell Lymphoblastic Leukemia-Lymphoma na nagre-recruit sa U.S.
23 pag-aaral para sa Precursor T-Cell Lymphoblastic Leukemia-Lymphoma ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Houston, TX8 pag-aaral
- New York City, NY6 pag-aaral
- Columbus, OH5 pag-aaral
- Philadelphia, PA4 pag-aaral
- Washington, DC4 pag-aaral
- Boston, MA3 pag-aaral
- Baldwin Park, CA3 pag-aaral
- St. Louis, MO3 pag-aaral
- East Norwalk, CT3 pag-aaral
- Edison, NJ3 pag-aaral
- New Rochelle, NY3 pag-aaral
- Queens, NY3 pag-aaral
- Staten Island, NY3 pag-aaral
Ayos sa estado
- California5 pag-aaral
- Colorado3 pag-aaral
- Florida3 pag-aaral
- Massachusetts3 pag-aaral
- Missouri3 pag-aaral
- New Jersey3 pag-aaral
- New York7 pag-aaral
- North Carolina3 pag-aaral
- Ohio6 pag-aaral
- Pennsylvania5 pag-aaral
- Tennessee3 pag-aaral
- Texas8 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Nagre-recruitPhase 1
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Set 29, 2026 · NCT06904066A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Nagre-recruitPhase 2
6 Months · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06514794Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT04301076Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT01087333A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
Nagre-recruitPhase 2
1 Month – 21 Years · Lahat ng kasarian · Na-update Set 18, 2026 · NCT06561074Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT05289687Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
Nagre-recruitPhase 1
Hanggang edad 39 · Lahat ng kasarian · Na-update Set 11, 2026 · NCT04972942Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
Nagre-recruitPhase 1
Edad 12 hanggang 30 · Lahat ng kasarian · Na-update Ago 12, 2026 · NCT07513129Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
Nagre-recruitPhase 1
Hanggang edad 75 · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT03081910Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
Nagre-recruitPhase 2
Edad 1 hanggang 18 · Lahat ng kasarian · Na-update Ago 10, 2026 · NCT06390319Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Nagre-recruitPhase 2
Lahat ng edad · Lahat ng kasarian · Na-update Hul 15, 2026 · NCT00501826Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Nagre-recruitPhase 1
Edad 0 hanggang 29 · Lahat ng kasarian · Na-update Hul 7, 2026 · NCT06934382Registry of Older Patients With Cancer
Nagre-recruitObservasyonal na pag-aaral
Edad 65 pataas · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT01137825A Registry for People With T-cell Lymphoma
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update May 20, 2026 · NCT05978141CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
Nagre-recruitPhase 1
Hanggang edad 21 · Lahat ng kasarian · Na-update May 19, 2026 · NCT04318678Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells
Nagre-recruitPhase 1
Hanggang edad 75 · Lahat ng kasarian · Na-update May 18, 2026 · NCT07220993Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 15, 2026 · NCT07356245Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 14, 2026 · NCT05996185A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 5, 2026 · NCT06698003Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 10, 2026 · NCT04848064Two Step Haplo With Radiation Conditioning
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 30, 2025 · NCT05031897Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Okt 27, 2025 · NCT01137643Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 15, 2025 · NCT06462365Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.